Exhibit (c)(iv)

STRICTLY CONFIDENTIAL Pinto Illustrative Financial Analysis Selected Precedent Transactions Analysis – Transaction Metrics 1 Upfront TEV Contingent Value Total Value NTM Rev Consideration Premia Upfront / Announced Target Acquiror Indication ($mm) ($mm) ($mm) ($mm) Cash Equity 1 day 1 month NTM Rev. 02/15/2023 Emergent (Traveler's Vaccines) Bavarian Nordic Typhoid, Cholera $270 $110 $380 $49 100% - NA NA 5.5x Prd. 07/11/2022 La Jolla Innoviva Septic Shock 149 - 149 56 100% - 84% 76% 2.7x Pub. Prd. 02/14/2022 BDSI Collegium Chronic Pain 552 - 552 194 100% - 54% 66% 2.8x Pub. 10/11/2021 Flexion Pacira OA Knee Pain 587 422 1,009 151 100% - 47% 38% 3.9x Pub. 10/11/2021 Adamas Supernus Parkinson's Dyskinesia 457 49 506 112 100% - 76% 72% 4.1x Pub. Pub. Pvt. Pvt. The Medicines Company 11/29/2017 Melinta cUTI, ABSSSI 270 - 270 80 80% 20% NA NA 3.4x Prd. (AI Business) Mean $407 $78 $485 $128 61% 58% 3.4x Median $363 $25 $443 $111 54% 66% 3.2x Pinto at Offer Price (Received 5/22/2023) 2 3 3 Long-Range Plan: $2.15 / share + 0.85 / share CVR $349 $52 $401 $170 100% - 13% 8% 2.0x Pub. And Pvt. denote deals involving a public / private target, respectively. Prd. denotes deals involving the acquisition of a product / product portfolio Source: Company filings, Press releases, Wall Street Research, Capital IQ, Pinto May 2023 LRP (received on 6/2/2023) 1. Represent unaffected premia based on upfront consideration; 1-month premia are based on the target’s VWAP over 30 trading days prior to the transaction announcement [ 43 ] 2. Does not include BARDA procurement revenue in NTM period; revenue consists of product revenue, government contract service & grant revenue, and collaboration & royalty revenue. NTM revenues determined as of 3/31/2023 3. Based on Pinto closing price of $1.91 as of 5/22/2023 and Pinto 30D VWAP of ~$1.98 as of 5/22/2023 per Bloomberg